Category: Biotech
-
Editing modality — nuclease, base, prime — and why the most precise editor is the least clinically mature
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. In-vivo gene editing is not one technology but a precision spectrum: nuclease (double-strand break, random indels — a “knockout” tool) → base editing (single-base substitution, no…
-
The in-vivo gene-editing landscape — one-shot, lifelong lipid lowering has arrived at the headline, but delivery, safety and irreversibility are the real bottlenecks
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All reduction and editing-efficiency figures are attributed to the sponsoring trial or company; many are company press releases or conference presentations rather than peer-reviewed data (noted inline). Safety events are…
